{"name":"Perrigo Company","slug":"perrigo","ticker":"PRGO","exchange":"NYSE","domain":"perrigo.com","description":"Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park.","hq":"Dublin, Ireland","founded":0,"employees":"8100","ceo":"Patrick Lockwood-Taylor","sector":"Consumer Healthcare / OTC","stockPrice":10.74,"stockChange":0.18,"stockChangePercent":1.7,"marketCap":"$1.5B","metrics":{"revenue":4700000000,"revenueGrowth":-2.5,"grossMargin":35.1,"rdSpend":95400000,"netIncome":-1425400000,"cash":600700000,"dividendYield":10.98,"peRatio":4.5,"fiscalYear":"FY2013"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2025-06-01","label":"Nizoral patent cliff ($100.0M at risk)","drug":"Nizoral","type":"patent_expiry","sentiment":"negative"},{"date":"2026-06-01","label":"Tums patent cliff ($200.0M at risk)","drug":"Tums","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Perrigo Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Perrigo Company plc (NYSE: PRGO) today announced its financial results for the fourth quarter and full year 2023.","drugName":"","sentiment":"neutral"},{"date":"2023-09-01","type":"deal","headline":"Perrigo Completes Sale of Infant Formula Business to Reckitt Benckiser","summary":"Perrigo Company plc (NYSE: PRGO) today announced that it has completed the sale of its infant formula business to Reckitt Benckiser Group plc.","drugName":"","sentiment":"positive"},{"date":"2023-06-01","type":"regulatory","headline":"FDA Approves Perrigo's Generic Version of Flonase","summary":"Perrigo Company plc (NYSE: PRGO) today announced that the U.S. Food and Drug Administration (FDA) has approved its generic version of Flonase.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-28","type":"pipeline","source":"simplywall.st","summary":"Is Perrigo (PRGO) Now Mispriced After Its Steep Multi‑Year Share Price Slide - simplywall.st","headline":"Is Perrigo (PRGO) Now Mispriced After Its Steep Multi‑Year Share Price Slide","sentiment":"neutral"},{"date":"2026-03-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE96REpXUURDQU9OM2hOTFItMG1ZT3VaMkRoQVVGOEotUjZBcTZ4QXc5MFVMRzFKdEZHT0Y3X0VpbWxBbDNvZW5fTHlHZHpkbzVMM2JIaHJSZU5TUGVieE1vcGl5YVBvTGdDVVJJTWdR?oc=5","date":"2026-03-21","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Perrigo Co Plc (PRGO) - Stock Titan","headline":"If You Invested $1,000 in Perrigo Co Plc (PRGO)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-28","type":"pipeline","source":"simplywall.st","summary":"Perrigo Cost Reset Program Faces Impairment Hit And Transition Year - simplywall.st","headline":"Perrigo Cost Reset Program Faces Impairment Hit And Transition Year","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPMVl0ZWx0WHROWkpQQW43Y2pzb0h6MDM1c0c5b0YxXzEyTEMtc0w5NTB5VTdnRTZpcG92VG9TOHlrX2ROZDRIbXZlZ0FULW9KVU5ndnI4VUNXRTU4ZUtxRTlOZzFEaU45NHczWWtEWUNDLUUtRzV1eU1lMmRTeWp5X05heFJBYlZXaVpEQ0pfbVg0QUhubE5QcVFJcDdVMGFGamFyeUR4azdtd0ZxemhFaUZNVlhEWThl?oc=5","date":"2026-02-27","type":"earnings","source":"TradingView","summary":"PRGO Q4 Earnings Miss, Sales Beat, Stock Down on Weak 2026 View - TradingView","headline":"PRGO Q4 Earnings Miss, Sales Beat, Stock Down on Weak 2026 View","sentiment":"negative"},{"url":"https://news.google.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?oc=5","date":"2026-02-27","type":"earnings","source":"simplywall.st","summary":"Perrigo (PRGO) Q4 Earnings Collapse With US$10.15 EPS Loss Tests Turnaround Narrative - simplywall.st","headline":"Perrigo (PRGO) Q4 Earnings Collapse With US$10.15 EPS Loss Tests Turnaround Narrative","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1yaEtHWmotNVNUR050aWJCbkxIRnhQcVo4Q1MxU1Q5QkdLZmN4ZHBUYnVuZXN6bmQ1UnlLa3diOXM4RElqQmZJTUM3WUJ3SGh6Uk1v?oc=5","date":"2026-02-10","type":"pipeline","source":"Forbes","summary":"Perrigo - Forbes","headline":"Perrigo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwJBVV95cUxPRUlRSHJONFJrYTFVNGN2UlUza0ltSGhYSE5pSVhjQzNROXhEUW5WZ0JyUTBoRFoyTWg1SUNEaVhoeTdqYVVyU0lzZnZ1Q2d1N0FZXzBWbzc4ejdhR0U0VVFQZUNEUnhJRjZ1YVdkZjFUQ2p3QnFiM09TSXVseGdiZzRpMzJOTWZDWG1qSGh1ZFVEZlJmRnNNSi1LTFlMbUFCTy1TXzdNVjZUQ2FOa0VPSTh6aThiVUdwV1pUTVdwaFpCREpBbzRwaGYzSk54aV9MMzdtR24zM2g4NDZUR2NDQS1XOFNORGJLSFJaLUsybTBrU2RlSFctWE53OWFUZEo5UXowVEN5SVpDbE1sTXhZUndUODV3REttUFd1Vjh2MERkSjJ6eC1WN0FBM3E5TFpBZjJYQ3ZReG9fT2kxMTlJ?oc=5","date":"2025-12-04","type":"pipeline","source":"GlobeNewswire","summary":"PRGO Class Action Reminder: Perrigo Company Stockholders - GlobeNewswire","headline":"PRGO Class Action Reminder: Perrigo Company Stockholders","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-07","type":"pipeline","source":"simplywall.st","summary":"Perrigo Company plc (NYSE:PRGO) Not Doing Enough For Some Investors As Its Shares Slump 31% - simplywall.st","headline":"Perrigo Company plc (NYSE:PRGO) Not Doing Enough For Some Investors As Its Shares Slump 31%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxObGtwSmwtTlNNMUN3alY0NGNzdDR4elVpYUpDamZJOE11ZVNXa2RwX1FKQ3Zoekg1YXZ2MlJBejlCbk1kU0E5bEkxREpfM0RYYnd5bkJYbVlhVElYN2NKbUlxVEFWUDNldl9qZ1BTdlpaUUk3UG55M1lFSjVMejYxRC13?oc=5","date":"2025-09-16","type":"deal","source":"Yahoo Finance","summary":"Perrigo Company plc (PRGO) Sells Dermacosmetics Unit in €327M Deal - Yahoo Finance","headline":"Perrigo Company plc (PRGO) Sells Dermacosmetics Unit in €327M Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQNm5TWFM1eElvQUtqclZ5aS1oMUdDcXhSWVJCQzlWUzhhUWJtamxBTWw1ZnJfSVliYUs1WVdndWZqMllVNjFtWGZKa2NHa2dsMVA4TWVPWGJZd0ZjUGtETC1Yd0Q5RkVkZ0NTTjhZU25uRHZ0R2g5eWtITDN1VHFxTVlMazVmSlRsOHU4RXZ2cHp2MVVXTFF5aGwySFJXcUFqSWVvSUV6Zk11b0NwSTV5YklLamhJU1hhX2RMWE9R?oc=5","date":"2024-07-10","type":"pipeline","source":"PR Newswire","summary":"Perrigo Completes Divestment of HRA Pharma Rare Diseases Business - PR Newswire","headline":"Perrigo Completes Divestment of HRA Pharma Rare Diseases Business","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxOTkh3V3UxeThCTGFXUndibjZKMlVhbDQwaUx2OVQ4aDZpZ2FRLU4xb2E0VXZqZG9pRGVUdVJIN181aVFNb2U5LV8zNVhFTkZBcDBVLVVJX0lWU1gySUlFVGhaTE54M1pZT28xa1RKQ0FBRmRTSWZ5MTlDbU8weU9FLWNJeFFheHpzbDFjMmxlRUk2Ylgyaks3M1EzRDFaNTNEWnBLY2Y4bVU0WlpfMXV2T2JXSlpzX3A3ZEhwVkVjd3ktTGZ6ZmFJdWRjcDRvNzFMYU0wVVVNOA?oc=5","date":"2022-07-11","type":"regulatory","source":"PR Newswire","summary":"Perrigo's HRA Pharma Submits Application to FDA for First-Ever OTC Birth Control Pill - PR Newswire","headline":"Perrigo's HRA Pharma Submits Application to FDA for First-Ever OTC Birth Control Pill","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPckxyNEdGYlBSYUVqdzZ0RDFSaWtLSEZhNl9hVVYzWXllVGNkczdSTDU5VUU2VUxHd2VIQktHQ3A3YUktX1dTR1VVZXlMNEtpUkhNUWdaSWdaY0dGYzI0Q1gyUmc2c2hxUFpLMUhpNW01aTc0YU9ORXVHdG9uMWJlcGhjRzFQR1FwVDkwdHY4ME5JWnRLdXhIQU5JNENWNE9xQ1c4NmZmbl9ma2gwYjczSTBkZ3ZpRW9nNzNEcUp5WHhVellLdVJj?oc=5","date":"2018-08-09","type":"pipeline","source":"PR Newswire","summary":"Perrigo Announces Plan To Separate Prescription Pharmaceuticals Business - PR Newswire","headline":"Perrigo Announces Plan To Separate Prescription Pharmaceuticals Business","sentiment":"neutral"}],"patents":[{"drugName":"Nizoral","drugSlug":"ketoconazole","patentNumber":"","type":"Patent Cliff","expiryDate":"2025-06-01","territory":"US","annualRevenue":100000000},{"drugName":"Tums","drugSlug":"calcium-carbonate","patentNumber":"","type":"Patent Cliff","expiryDate":"2026-06-01","territory":"US","annualRevenue":200000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Johnson & Johnson","Reckitt Benckiser","Church & Dwight"],"therapeuticFocus":["Respiratory","Allergy","Pain Management"],"financials":{"source":"sec_edgar","revenue":800000,"revenuePeriod":"2013-06-29","revenueHistory":[{"value":800000,"period":"2013-06-29"}],"grossProfit":1494500000,"grossProfitHistory":[],"rdSpend":95400000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-1425400000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":600700000,"cashHistory":[],"totalAssets":8535200000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":10.74,"previousClose":10.56,"fiftyTwoWeekHigh":28.44,"fiftyTwoWeekLow":9.23,"fiftyTwoWeekRange":"9.23 - 28.44","fiftyDayAverage":12.3,"twoHundredDayAverage":18.33,"beta":0.49,"enterpriseValue":4772177408,"forwardPE":4.5,"priceToBook":0.5,"priceToSales":0.35,"enterpriseToRevenue":1.12,"enterpriseToEbitda":7.02,"pegRatio":0,"ebitda":679699968,"ebitdaMargin":16,"freeCashflow":28325000,"operatingCashflow":238500000,"totalDebt":3850200064,"debtToEquity":131.2,"currentRatio":2.76,"returnOnAssets":2.4,"returnOnEquity":-38.7,"analystRating":"2.4 - Buy","recommendationKey":"buy","numberOfAnalysts":4,"targetMeanPrice":17,"targetHighPrice":20,"targetLowPrice":15,"dividendRate":1.16,"payoutRatio":109.5,"fiveYearAvgDividendYield":3.77,"exDividendDate":1772409600,"insiderHeldPercent":0.4,"institutionHeldPercent":115.7,"sharesOutstanding":137649352,"floatShares":136790420,"sharesShort":15790970,"shortRatio":3.95,"shortPercentOfFloat":11.5,"epsTrailing":-10.12,"epsForward":2.39,"revenuePerShare":30.71,"bookValue":21.33,"officers":[{"age":56,"name":"Mr. Patrick  Lockwood-Taylor","title":"President, CEO & Director"},{"age":49,"name":"Mr. Eduardo Guarita Bezerra","title":"Executive VP & CFO"},{"age":44,"name":"Ms. Abbie  Lennox","title":"EVP & Chief Scientific Officer"},{"age":48,"name":"Mr. Charles  Atkinson","title":"Executive VP, General Counsel & Secretary"},{"age":44,"name":"Mr. Roberto  Khoury","title":"Executive VP & Chief Commercial Officer"},{"age":null,"name":"Mr. Bradley  Joseph","title":"Vice President of Global Investor Relations & Corporate Communications"},{"age":56,"name":"Mr. Robert  Willis","title":"Chief Human Resources Officer & Executive VP"},{"age":45,"name":"Dr. David  Ball","title":"EVP and Chief Brand & Digital Officer"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"http://www.perrigo.com/investors/investor_landing.aspx","website":"https://www.perrigo.com","phone":"353 1 709 4000"}}